Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology

References

• MayerRJVenookAPSchilskyRLProgress against GI cancer during the American Society of Clinical Oncology’s first 50 yearsJ Clin Oncol201432151521153024752046
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive molecular characterization of gastric adenocarcinomaNature2014513751720220925079317
   PubMed Web of Science ®Google Scholar
• AprileGGiampieriRBonottoMThe challenge of targeted therapies for gastric cancer patients: the beginning of a long journeyExpert Opin Investig Drugs2014237925942
   PubMed Web of Science ®Google Scholar
• AnXWangFShaoQMET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapyCancer2014120567568224804300
   PubMed Web of Science ®Google Scholar
• LennerzJKKwakELAckermanAMET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinibJ Clin Oncol201129364803481022042947
   PubMed Web of Science ®Google Scholar
• GrazianoFGalluccioNLorenziniPGenetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancerJ Clin Oncol201129364789479522042954
   PubMed Web of Science ®Google Scholar
• KwakELLoRussoPHamidOClinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancerJ Clin Oncol201533suppl 3 abstr 1
   Web of Science ®Google Scholar
• ShahMAChoJYHuatITRandomized phase II study of FOLFOX +/− MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC)J Clin Oncol201533suppl 3 abstr 2
   Web of Science ®Google Scholar
• Available from: http://www.roche.com/media/store/releases/med-cor-2014-03-03.htmAccessed on February 8th 2015
   Google Scholar
• Available from: http://www.prnewswire.com/news-releases/amgen-announces-termination-of-all-amgen-sponsored-clinical-studies-of-rilotumumab-in-advanced-gastric-cancer-300000103.htmlAccessed on February 8th 2015
   Google Scholar
• HerseyPGowrishankarKPembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanomaFuture Oncol201511113314025572788
   PubMed Web of Science ®Google Scholar
• SunJXuKWuCPD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodiesTissue Antigens2007691192717212704
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• MuroKBangYShankaranVA phase 1B study of pembrolizumab (PEMBRO; MK-3475) in patients (PTS) with advanced gastric cancerAnn Oncol201425suppl 5v1v41
   Web of Science ®Google Scholar
• MuroKBangYJShankaranVRelationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012J Clin Oncol201533suppl 3 abstr 3
   Web of Science ®Google Scholar
• WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res200915237412747419934295
   PubMed Web of Science ®Google Scholar
• CunninghamDAllumWHStenningSPMAGIC Trial ParticipantsPerioperative chemotherapy versus surgery alone for resectable gastroesophageal cancerN Engl J Med20063551112016822992
   PubMed Web of Science ®Google Scholar
• YchouMBoigeVPignonJPPerioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trialJ Clin Oncol201129131715172121444866
   PubMed Web of Science ®Google Scholar
• OkinesAFThompsonLCCunninghamDEffect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trialAnn Oncol20132451253126123233651
   PubMed Web of Science ®Google Scholar
• RiveraFJimenez-FonsecaPGarcia AlfonsoPNEOHX study: perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER-2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma – 18 m DFS analysisJ Clin Oncol201533suppl 3 abstr 107
   Web of Science ®Google Scholar
• AprileGRijavecEFontanellaCRihawiKGrossiFRamucirumab: preclinical research and clinical developmentOnco Targets Ther201471997200625378934
   PubMed Web of Science ®Google Scholar
• ZhuAXRyooBYYenCJRamucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH studyJ Clin Oncol201533suppl 3 abstr 232
   Web of Science ®Google Scholar
• Casadei GardiniAMarisiGScarpiEeNOS polymorphisms in relation to outcome in advanced HCC patients receiving sorafenibJ Clin Oncol201533suppl 3 abstr 230
   Web of Science ®Google Scholar
• ChengALThongprasertSLimHYPhase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC)J Clin Oncol201533suppl 3 abstr 237
   Web of Science ®Google Scholar
• PalmerDHMaYTPeck-RadosavljevicMRandomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)J Clin Oncol201533suppl 3 abstr 238
   Web of Science ®Google Scholar
• PrajapatiHJSik KimHSNew prognostic staging system from the multivariate survival analysis (MVA) of the patients with unresectable hepatocellular carcinoma (HCC) treated with doxorubicin drug eluting beads transarterial chemoembolization (DEB TACE)J Clin Oncol201533suppl 3 abstr 236
   Web of Science ®Google Scholar
• VernereyDHammelPPaget-BaillySPrognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: an ancillary study of the LAP 07 trialJ Clin Oncol201533suppl 3 abstr 235
   Web of Science ®Google Scholar
• ChenLTVon HoffDDPin LiCExpanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapyJ Clin Oncol201533suppl 3 abstr 234
   Web of Science ®Google Scholar
• Wang-GillamANyweningTMSanfordDMPhase IB study of FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma (PC)J Clin Oncol201533suppl 3 abstr 338
   Web of Science ®Google Scholar
• RossJSWangKCatenacciDVTComprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterationsJ Clin Oncol201533suppl 3 abstr 231
   Web of Science ®Google Scholar
• PierantoniCPagliacciAScartozziMBerardiRBianconiMCascinuSPancreatic cancer: progress in cancer therapyCrit Rev Oncol Hematol2008671273818356073
   PubMed Web of Science ®Google Scholar
• FaloppiLScartozziMMaccaroniEEvolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic optionsCancer Treat Rev2011373167177
   Web of Science ®Google Scholar
• ScartozziMFaloppiLSvegliati BaroniGVEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 studyInt J Cancer201413551247125624510746
   PubMed Web of Science ®Google Scholar
• TaberneroJCohnALObermannovaRRAISE: a randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp)J Clin Oncol201533suppl 3 abstr 512
   Web of Science ®Google Scholar
• XuRShenLWangKA randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase II clinical study of famitinib in the treatment of advanced metastatic colorectal cancerJ Clin Oncol201533suppl 3 abstr 513
   Web of Science ®Google Scholar
• AprileGLutrinoSEFerrariLEvidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patientsWorld J Gastroenterol201319468474848824379565
   PubMed Web of Science ®Google Scholar
• GiampieriRAprileGDel PreteMBeyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patientsCurr Drug Targets201415131225123025382208
   PubMed Web of Science ®Google Scholar
• FolprechtGAustDERothAImproving access to molecularly defined clinical trials for patients with colorectal cancer: the EORTC SPECTAcolor platformJ Clin Oncol201533suppl 3 abstr 575
   Web of Science ®Google Scholar
• ShitaraKFujiiSDendaTThe nationwide genomic screening project for gastrointestinal cancer in Japan (GI-SCREEN): simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01)J Clin Oncol201533suppl 3 abstr 578
   Web of Science ®Google Scholar
• YaegerRDCercekAO’ReillyEMPilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancerJ Clin Oncol201533suppl 3 abstr 611
   Web of Science ®Google Scholar
• YaegerRCercekAO’ReillyEMS1406: randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC)J Clin Oncol201533suppl 3 abstr TPS790
   Web of Science ®Google Scholar
• SienaSSartore-BianchiATrusolinoLTherapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): the HERACLES trialJ Clin Oncol201533suppl 3 abstr 565
   Google Scholar
• Ingold HeppnerBBehrensHMBalschunKHER2/neu testing in primary colorectal carcinomaBr J Cancer2014111101977198425211663
   PubMed Web of Science ®Google Scholar
• SmithJJChowOSEatonAOrgan preservation in patients with rectal cancer with clinical complete response after neoadjuvant therapyJ Clin Oncol201533suppl 3 abstr 509
   Google Scholar
• HuntingtonCHBoselliDHillJSJonathanCOptimal timing of surgical resection after radiation therapy in locally advanced rectal adenocarcinoma: an analysis of the National Cancer Database (NCDB)J Clin Oncol201533suppl 3 abstr 510
   Web of Science ®Google Scholar